New to site?


Login

Lost password? (X)

Already have an account?


Signup

(X)
Farooq

Treatment with Novartis’ Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation

HomenewsTreatment with Novartis’ Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation
22
Feb
Treatment with Novartis’ Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation
  • Author
    web
  • Comments
    0 Comments
  • Category

NovartisNovartis today announced the publication of the CLAIM* study in the Lancet Respiratory Medicine, which demonstrated that treatment once-daily Ultibro® Breezhaler® (indacaterol/glycopyrronium 110/50 mcg) significantly improved lung and cardiac function, when compared to placebo, in chronic obstructive pulmonary disease (COPD) patients with lung hyperinflation[1].Original Article

Tags:

    Related Posts
    Leave A Comment

    Leave A Comment